vs
Side-by-side financial comparison of COASTAL FINANCIAL CORP (CCB) and CASTLE BIOSCIENCES INC (CSTL). Click either name above to swap in a different company.
COASTAL FINANCIAL CORP is the larger business by last-quarter revenue ($138.0M vs $87.0M, roughly 1.6× CASTLE BIOSCIENCES INC). On growth, CASTLE BIOSCIENCES INC posted the faster year-over-year revenue change (0.8% vs -5.8%). COASTAL FINANCIAL CORP produced more free cash flow last quarter ($246.1M vs $19.7M). Over the past eight quarters, CASTLE BIOSCIENCES INC's revenue compounded faster (9.2% CAGR vs -3.6%).
Fidelity National Financial, Inc., is an American provider of title insurance and settlement services to the real estate and mortgage industries. A Fortune 500 company, Fidelity National Financial generated approximately $8.469 billion in annual revenue in 2019 from its title and real estate-related operations. The company was the first instance of an attorney licensed by a Native American Tribe being certified as "authorized house counsel" in the state of Florida.
Castle Biosciences Inc. is a commercial-stage diagnostic firm that develops and markets proprietary, clinically actionable tests for dermatological conditions such as melanoma and other skin cancers, plus rare diseases. It operates mainly in the U.S. healthcare market, focusing on segments with high unmet need for more accurate diagnostics to guide treatment choices.
CCB vs CSTL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $138.0M | $87.0M |
| Net Profit | — | — |
| Gross Margin | — | 79.0% |
| Operating Margin | 12.4% | -4.4% |
| Net Margin | — | — |
| Revenue YoY | -5.8% | 0.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.84 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $138.0M | $87.0M | ||
| Q3 25 | $144.7M | $83.0M | ||
| Q2 25 | $119.4M | $86.2M | ||
| Q1 25 | $139.5M | $88.0M | ||
| Q4 24 | $146.5M | $86.3M | ||
| Q3 24 | $151.1M | $85.8M | ||
| Q2 24 | $135.3M | $87.0M | ||
| Q1 24 | $148.4M | $73.0M |
| Q4 25 | — | — | ||
| Q3 25 | $13.6M | $-501.0K | ||
| Q2 25 | $11.0M | $4.5M | ||
| Q1 25 | $9.7M | $-25.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.5M | $2.3M | ||
| Q2 24 | $11.6M | $8.9M | ||
| Q1 24 | $6.8M | $-2.5M |
| Q4 25 | — | 79.0% | ||
| Q3 25 | — | 77.5% | ||
| Q2 25 | — | 79.5% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 81.3% | ||
| Q3 24 | — | 81.8% | ||
| Q2 24 | — | 83.3% | ||
| Q1 24 | — | 81.0% |
| Q4 25 | 12.4% | -4.4% | ||
| Q3 25 | 12.4% | -8.2% | ||
| Q2 25 | 12.0% | -4.9% | ||
| Q1 25 | 8.4% | -31.7% | ||
| Q4 24 | 11.7% | 4.7% | ||
| Q3 24 | 10.8% | 5.9% | ||
| Q2 24 | 11.1% | 5.8% | ||
| Q1 24 | 5.9% | -7.5% |
| Q4 25 | — | — | ||
| Q3 25 | 9.4% | -0.6% | ||
| Q2 25 | 9.2% | 5.2% | ||
| Q1 25 | 7.0% | -29.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.9% | 2.6% | ||
| Q2 24 | 8.6% | 10.3% | ||
| Q1 24 | 4.6% | -3.5% |
| Q4 25 | $0.84 | $-0.06 | ||
| Q3 25 | $0.88 | $-0.02 | ||
| Q2 25 | $0.71 | $0.15 | ||
| Q1 25 | $0.63 | $-0.90 | ||
| Q4 24 | $0.95 | $0.32 | ||
| Q3 24 | $0.97 | $0.08 | ||
| Q2 24 | $0.84 | $0.31 | ||
| Q1 24 | $0.50 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $299.5M |
| Total DebtLower is stronger | — | $10.1M |
| Stockholders' EquityBook value | $491.0M | $470.9M |
| Total Assets | $4.7B | $578.6M |
| Debt / EquityLower = less leverage | — | 0.02× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $299.5M | ||
| Q3 25 | — | $287.5M | ||
| Q2 25 | — | $275.9M | ||
| Q1 25 | — | $275.2M | ||
| Q4 24 | — | $293.1M | ||
| Q3 24 | — | $95.0M | ||
| Q2 24 | — | $85.6M | ||
| Q1 24 | — | $82.9M |
| Q4 25 | — | $10.1M | ||
| Q3 25 | — | $10.0M | ||
| Q2 25 | — | $10.0M | ||
| Q1 25 | — | $10.0M | ||
| Q4 24 | — | $10.0M | ||
| Q3 24 | — | $10.0M | ||
| Q2 24 | — | $10.0M | ||
| Q1 24 | — | $10.0M |
| Q4 25 | $491.0M | $470.9M | ||
| Q3 25 | $475.3M | $467.0M | ||
| Q2 25 | $461.7M | $455.4M | ||
| Q1 25 | $449.9M | $440.3M | ||
| Q4 24 | $438.7M | $455.8M | ||
| Q3 24 | $331.9M | $441.1M | ||
| Q2 24 | $316.7M | $423.9M | ||
| Q1 24 | $303.7M | $402.5M |
| Q4 25 | $4.7B | $578.6M | ||
| Q3 25 | $4.6B | $562.8M | ||
| Q2 25 | $4.5B | $544.7M | ||
| Q1 25 | $4.3B | $501.7M | ||
| Q4 24 | $4.1B | $531.2M | ||
| Q3 24 | $4.1B | $514.6M | ||
| Q2 24 | $4.0B | $487.3M | ||
| Q1 24 | $3.9B | $458.5M |
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.02× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $254.6M | $26.9M |
| Free Cash FlowOCF − Capex | $246.1M | $19.7M |
| FCF MarginFCF / Revenue | 178.3% | 22.7% |
| Capex IntensityCapex / Revenue | 6.1% | 8.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $436.4M | $28.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $254.6M | $26.9M | ||
| Q3 25 | $59.0M | $22.6M | ||
| Q2 25 | $66.0M | $20.8M | ||
| Q1 25 | $71.7M | $-6.0M | ||
| Q4 24 | $259.8M | $24.4M | ||
| Q3 24 | $62.6M | $23.3M | ||
| Q2 24 | $72.1M | $24.0M | ||
| Q1 24 | $56.8M | $-6.8M |
| Q4 25 | $246.1M | $19.7M | ||
| Q3 25 | $57.4M | $7.8M | ||
| Q2 25 | $64.0M | $11.6M | ||
| Q1 25 | $68.9M | $-10.8M | ||
| Q4 24 | $249.9M | $16.8M | ||
| Q3 24 | $60.2M | $17.0M | ||
| Q2 24 | $69.5M | $18.8M | ||
| Q1 24 | $55.0M | $-16.0M |
| Q4 25 | 178.3% | 22.7% | ||
| Q3 25 | 39.7% | 9.4% | ||
| Q2 25 | 53.6% | 13.4% | ||
| Q1 25 | 49.4% | -12.2% | ||
| Q4 24 | 170.6% | 19.5% | ||
| Q3 24 | 39.8% | 19.8% | ||
| Q2 24 | 51.3% | 21.6% | ||
| Q1 24 | 37.1% | -21.9% |
| Q4 25 | 6.1% | 8.3% | ||
| Q3 25 | 1.2% | 17.9% | ||
| Q2 25 | 1.7% | 10.7% | ||
| Q1 25 | 2.0% | 5.4% | ||
| Q4 24 | 6.8% | 8.8% | ||
| Q3 24 | 1.6% | 7.4% | ||
| Q2 24 | 1.9% | 6.0% | ||
| Q1 24 | 1.2% | 12.5% |
| Q4 25 | — | — | ||
| Q3 25 | 4.34× | — | ||
| Q2 25 | 5.99× | 4.60× | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.65× | 10.29× | ||
| Q2 24 | 6.22× | 2.69× | ||
| Q1 24 | 8.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCB
| Other | $74.7M | 54% |
| Baa S Credit Enhancements | $47.3M | 34% |
| Baa S Program Income | $8.4M | 6% |
| Transaction Fees | $4.9M | 4% |
| Servicing And Other Baa S Fees | $1.6M | 1% |
| Baa S Fraud Enhancements | $1.1M | 1% |
CSTL
| Dermatologic | $48.6M | 56% |
| Non Dermatologic | $38.4M | 44% |
